The present invention is related in general to a medical device to access the bone marrow and specifically to an apparatus and method for penetrating the bone marrow with a powered drill and inserting a penetrator or needle.
Every year, millions of patients are treated for life-threatening emergencies in the United States. Such emergencies include shock, trauma, cardiac arrest, drug overdoses, diabetic ketoacidosis, arrhythmias, burns, and status epilepticus just to name a few. For example, according to the American Heart Association, more than 1,500,000 patients suffer from heart attacks (myocardial infarctions) every year, with over 500,000 of them dying from its devastating complications.
An essential element for treating all such emergencies is the rapid establishment of an intravenous (IV) line in order to administer drugs and fluids directly into the circulatory system. Whether in the ambulance by paramedics, or in the emergency room by emergency specialists, the goal is the same—to start an IV in order to administer life-saving drugs and fluids. To a large degree, the ability to successfully treat such critical emergencies is dependent on the skill and luck of the operator in accomplishing vascular access. While it is relatively easy to start an IV on some patients, doctors, nurses and paramedics often experience great difficulty establishing IV access in approximately 20 percent of patients. These patients are probed repeatedly with sharp needles in an attempt to solve this problem and may require an invasive procedure to finally establish an intravenous route.
A further complicating factor in achieving IV access occurs “in the field” e.g. at the scene of an accident or during ambulance transport where it is difficult to see the target and excessive motion makes accessing the venous system very difficult.
In the case of patients with chronic disease or the elderly, the supply of easily-accessible veins may be depleted. Other patients may have no available IV sites due to anatomical scarcity of peripheral veins, obesity, extreme dehydration or previous IV drug use. For these patients, finding a suitable site for administering lifesaving drugs becomes a monumental and frustrating task. While morbidity and mortality statistics are not generally available, it is known that many patients with life-threatening emergencies have died of ensuing complications because access to the vascular system with life-saving IV therapy was delayed or simply not possible. For such patients, an alternative approach is required.
In accordance with teachings of the present invention, an apparatus and method are provided to allow rapid access to the bone marrow so that drugs and fluids can be infused into the circulatory system.
One aspect of the present invention includes an apparatus and method that will quickly puncture a bone with minimal trauma to the surrounding tissues and place a needle directly into the bone marrow to allow infusing drugs and fluids into the bone marrow.
One embodiment of the present invention includes a device that is a hand-held, battery-operated device that supplies rotational force to a needle in order to penetrate the bone marrow. In another embodiment of the present invention it is powered by means of a spring which can be rewound or by other mechanical means that do not include an electrical or battery power source. A spring-loaded driver may be used to wind up a spring as a power source to rotate the needle because it is cheap, reliable and has a long shelf life. One embodiment of a spring-powered device may include various mechanisms for modulating the speed of needle rotation.
Another embodiment of the invention calls for it to be reusable or disposable. In some embodiments the device itself may be reusable and the tissue penetrator or needle is disposable. A needle cover or shield can be incorporated into all embodiments.
In yet another embodiment of the invention, a unit dose of medication can be attached or incorporated into the device by means of a proprietary connection.
In the embodiments mentioned above, the intraosseous needle can be stabilized, once inserted, by means of a shield and a VELCRO strap.
In another embodiment of the invention, the device can be adapted to remove a specimen of tissue from the bone marrow (a bone marrow biopsy). In this embodiment a needle with three holes may be used to aspirate three different sites in the bone marrow.
In yet another clinical embodiment the device can be used to place an intracranial probe for pressure monitoring into the brain. In this embodiment there can be a two-way flow of fluids into or out of the brain depending on the clinical situation.
In the various embodiments listed, different sizes of the device and/or the needle are to accommodate different patient sizes or adult and pediatric sizes.
Various embodiments of the device can be configured for ergonomic comfort and ease of use. Alternate configurations of the motor-needle interface which may be required to achieve an ergonomic design include a flexible shaft or a 45 degree gear arrangement between the motor and the needle.
One embodiment of the present invention includes a device that may rapidly penetrate bone tissue and includes a fluid reservoir, which may be connected through an external port to a source of intravenous fluid. Another embodiment of the present invention includes a device for rapid penetration of bone, which may be used to directly insert a needle into a patient's bone marrow and then be disconnected from the needle. This allows a source of intravenous fluids to be connected to the needle that is positioned in the bone marrow. Still another embodiment of the present invention includes a device for rapid penetration of bone tissue having one or more fluid reservoirs that may be removed and exchanged with pre-filled drug ampules or fluid reservoirs.
In an alternate embodiment, the needle is operable to be detached from the hand-held housing after implantation such that the needle hub can be connected to an external source of drugs or medication. This feature may include a quick release mechanism. After detaching the needle from the device, a particular type of needle known as a “breakaway” needle may be implanted. The advantage to this type of needle is that it allows the insertion of a plastic intraosseous catheter into the bone marrow and removal of the surrounding needle. This may be advantageous because it would allow the fixation of the catheter to the skin with another more desirable apparatus that is stable and resistant to infection.
Technical benefits of the present invention include a device for rapid penetration of bone tissue that is portable and may be carried in the pocket or a portable emergency kit of a health care provider for emergency access to a patient's circulatory system.
Technical benefits of the present invention include obtaining access to the circulatory system that is fast, inexpensive and poses minimal risk to a patient.
An apparatus formed in accordance with teachings of the present invention may be used to quickly penetrate the outer layer of the bone so that drugs and fluids can be injected directly into the bone marrow.
The present invention provides an apparatus and method for use in emergency rooms, on the battlefield, in Emergency Medical Services settings, oncology treatment and veterinary applications.
Summary of Technical Benefits of Invention
Hand Held
Battery Powered Motor
Spring Powered Motor
Electrical Powered Motor
Hollow Drill (Needle)
Disposable Version
Reusable Version
Significant Market Appeal
Reliable
Automatic Detachable Mechanism
Meets FDA 510 k Approval
Unit Cost $25 for Some Models
A more complete and thorough understanding of the present invention and advantages thereof may be acquired by referring to the following description taken in conjunction with the accompanying drawings, in which like reference numbers indicate like features, and wherein:
Preferred embodiments of the invention and its advantages are best understood by reference to
Although the present invention and its advantages have been described in detail, it should be understood that various changes, substitutions and alternations can be made herein without departing from the spirit and scope of the invention as defined by the following claims.
Configurations
These are only a few examples of the many configurations that are possible. The key is to design the driver for the best and most comfortable human (hand) interface, providing the best control and best visualization.
The body of the driver can be plastic, ABS, metal, or any other suitable material. Bearings can be metal, ceramic, plastic, ABS or any other suitable material.
The needle shield can be of any configuration as long as it provides protection to the user from being accidentally stuck by the needle, either before or after use. It will be retractable or removable. The driver can also stabilize the skin during the drilling process.
Switch (trigger) Manual Operation
The switch can be mechanical or electrical. It can be enclosed (to make it water proof) or exposed for easier use. Several embodiments are considered.
Switch (trigger) Automatic Operation
The switch may be activated by an event, such as the shield retracting or a deliberate action, such as the user pulling a pin, thus preventing accidental discharge and providing additional safety features.
Control Depth of Penetration
In addition to
Release Mechanism (Needle from the Driver)
A well-designed release mechanism is necessary to assure worry free operation of the device. Ideally, the needle should separate from the chuck (holding mechanism) automatically upon proper penetration and depth of the needle into the bone. Otherwise the user might accidentally withdraw the needle from the bone while taking away the driver. Additional steps to separate the trocar and the needle from the body (motor and driver) would introduce the possibility of error and require greater skill levels to properly use the device. Therefore a trouble free chuck is required. It must be sturdy and proprietary to prevent miss-use.
Proprietary Needle Holder
In order for the VidaPen IO needle to be competitive in the market place, it must utilize a standard Luer lock mechanism. IV fluids and standard syringes use the Luer lock to function (connect to the needle) for giving drugs, fluids and blood. A Luer lock consists of a male portion (connected to the needle) and a female portion connected to the syringe or IV line. In order to protect VidaPen from competitors (misuse) the female Luer lock must be connected to the chuck (holding mechanism) of the driver by a proprietary design. The embodiment of this claim utilizes a key-and-lock mechanism for easy insertion and release.
Reduction Gear for Power and Speed
In order to provide the power necessary to drill through the hardest bone, VidaPen's needle will need to have the required torque. It will be necessary to increase the torque provided by a small DC motor (or other motor i.e. C02 powered motor) by incorporating a gear into the drive train. Fortunately, most DC motors operate at high RPM and are thus suitable to be geared down. The needle's ideal rotational speed is slower than most OEM motors. Therefore, the gearbox (or gearing arrangement) will be ideal to slow the drill to optimum speeds.
Needle Tips (Cutting Surface)
Many types of cutting tips have been devised for bone drills. This design embodies the concept of using the outer needle and the inner trocar as a single unit for optimal penetration of bone with minimal disruption of the anatomy. This is important from the standpoint of keeping the side port open for injections and aspiration. In addition, this embodiment will allow for a tight fit between the needle and the bone for better fixation and prevention of leakage (extravasation).
Reusable Driver/Disposable Needle
One embodiment of the device calls for it being disposable. Another embodiment is designed for the body (driver) to be reusable and the needle to be disposable. This is made possible by providing a chuck that mates with a proprietary shaft attached to the needle's Luer Lock. The needles must maintain sterility during storage and mounting of the needle while the driver does not have to be sterile. The driver will be rugged in design and the battery (or other power source) will be rechargeable or the battery will be easy to replace with off-the-shelf batteries.
Spring Loaded Driver
This embodiment uses a wind up spring as a power source to rotate the needle. This approach bypasses the inherent problems of motors: expense; reliability; weight; and size; and the limitations of batteries: size; weight; shelf life; reliability; decreased efficiency at low temperatures, and cost. Springs are cheap, reliable, long shelf life, small, low weight, predictable and operate well under a wide range of environmental conditions including heat and cold. The reason a wind-up-spring is an excellent choice for this application is because the VidaPen needle requires high torque for only a short period. The maximum time needed is less than 6 seconds, which translates into @100 revolutions. Further, a spring meets the requirements of high reliability under a wide range of circumstances. Motors and batteries can serve this purpose, however, it is a waste of resources and adds unnecessary complexity to have such a power source that is only required for 6 seconds.
Paramedics, EMS, and the Military
Special uses for the VidaPen include operating in the field, where ruggedness and durability are of paramount importance. The device may be designed to be water proof, temperature resistant, crush proof and be made in different shapes and colors. In addition, the pre-hospital and combat situations are ideally suited to use the “unit dose” version (VidaPen II). That is because often what the medic needs is simply a one-time dose of medication, such as an antidote for poison or epinephrine, in order to stabilize the patient. Unit dose ampules are widely used by paramedics to give a predetermined amount of drug for a particular indication. There are a limited number of drugs needed to fulfill that need.
VidaPen I for Injecting Multiple Drugs and Fluids
VidaPen I is designed to provide rapid vascular access in less than 6 seconds.
Trocar
Drilling into bone with a hollow drill (needle) sometimes plugs the orifice and the side ports. To overcome that problem a trocar is often used. A trocar is a rod within the needle. It is removed after placement in the bone.
Stabilizing the IO Needle
Stabilization of the IO needle is paramount for its success. Stabilization (how firmly the needle is seated in the bone) is affected by several factors including maintaining proper alignment during insertion (drilling). Other factors include: thickness and hardness of the bone; the length of the needle (longer needles are prone to rocking movements during use by virtue of their longer leverage arm); diameter of the hole during drilling compared to the diameter of the shaft at the point of seating (how loose or how tight a fit); smooth walled needle vs. threaded needle; and movement of the patient during use (causing rocking of the needle and subsequent loosening).
Prevent and Manage Extravasation
The end result of a good seal between the needle and the bone is that fluid and drugs injected through the needle will flow into the circulatory system. The result of a broken seal (or loose seal) is that some of the fluid will extravasate (leak) into the surrounding tissues and may cause a compartment syndrome. This condition is one of the most frequent complications of IO use and one of the most serious. In the compartment syndrome pressure from the leaking fluid builds up in the leg (which has limited capacity for expansion) and cuts off the circulation to the foot. Therefore, precaution must be taken to prevent this complication and health providers must monitor their patients for the development of extravasation. This problem has never been adequately addressed by current manufactures of IO needles.
Stabilization of VidaPen in Moving Patients
Being able to place the IO needle precisely in the target area of the tibia is a concern when patients are moving or have the potential to move. Drilling in the wrong place could subject the patient to harm. Special cases of such movement include patients suffering from status epilepticus, and violent patients (drug overdoses or mental status changes) that need to be controlled for their safety and treatment. Epileptic patients may shake violently for prolonged periods, which makes starting an IV nearly impossible. Likewise it may be difficult in these patients to accurately place the VidaPen for IO insertion. Although the target area for successful IO placement is much larger than the target for placement of an IV, this problem will be minimized with a stabilization device. The device must be easy to apply, even in difficult situations in the field.
VidaVac (Oncology Biopsy Needle)
Oncologists sometimes are not able to successfully obtain a suitable specimen because of mechanical problems. Biopsy needles used today often come out empty because they failed to capture a specimen of bone. When they are successful, the specimen obtained is often inconsistent. Significantly, two procedures are often required because one instrument is required to obtain the bone specimen (biopsy) and another instrument (resulting in a second procedure) is required to obtain the liquid marrow specimen. VidaVac addresses these problems with a powered biopsy needle combined with a specimen needle that can be performed in one procedure.
Further, the needle may be coated with Heparin or other anticoagulant to prevent clotting.
VidaVac I (Powered Biopsy Device)
Currently, oncologists use a biopsy needle that is manually inserted, often with considerable force and difficulty. The procedure is painful for patients and time consuming for the doctor. Risks are high because of excessive handling of blood contaminated sharp instruments are required. Accidental needle sticks and missed targets further complicate the procedure. VidaVac solves these problems with a powered biopsy needle.
Special Considerations for Cancer
Extravasation (leakage) of cytotoxic drugs into the subcutaneous tissues during cancer treatment can be devastating. To prevent extravasation (leakage) of cytotoxic drugs using the VidaPen I, special precautions must be taken.
Use of a treaded needle, which has been shown to decrease leakage
Use of a tapered needle with progressively larger diameter to make a tighter seal
Use of methylmethacrolate or other sealant to provide a tight seal.
The injection of methylene blue dye into the needle prior to use to detect any leak.
VidaProbe VidaVent (for Neurosurgery)
Neurosurgeons frequently insert vents into the cranium after massive closed head injuries to monitor intracranial pressure. Preventing excessive pressure can make a profound difference in the outcome of a brain-injured patient. Currently, the placement of such a device takes several steps and considerable time. VidaVent is designed to automate the procedure by providing a power drill to drive in the probe in one short step. The results will be a faster, safer and more palatable procedure.
The probe may detect pressure, chemicals, temperature, O2 stats, CO2 levels, or lactic acid.
The connector may be mechanical or electrical.
VidaPed (Pediatric Version)
Currently, infants and young children are candidates for standard manually inserted IO needles. Yet, some reluctance on the part of medics and doctors remains because the manual insertion process takes time and skill. In the process, the needle grinding through the bone causes concern to the provider. In addition, when the hard cortex is breached (entered) the needle may penetrate the opposite cortex (which causes extravasation) because of the large manual pressure being exerted. Therefore, the VidaPen is designed to permit use in small infants in a kinder/gentler way. Minimal pressure is required, because of the powered drill and so precise control of the depth of penetration can be maintained. The entire procedure is one-step and automatic, making it easier for the medic and the patient.
VidaVet (for Veterinary Applications)
Veterinarians frequently need to access the vascular system of companion animals for the purpose of diagnostics and treatment. These small animals often have tiny veins that are very difficult to access. While there is great need for this device in the veterinary market, vets require devices that are cheap and reusable. Therefore, the VidaVet will consist of a reusable driver and sterile disposable (throw away) needles.
After implantation of the IO needle, a special cap or cover will be strapped on to protect the device from self-destruction by the animal (prevent the animal from inadvertently pulling out the needle.
Spring Powered VidaPen I—Reusable
It may be advantageous to be able to rewind the spring for additional IO attempts should the first attempt fail. The ability to reload or rewind the spring is also necessary for applications using a reusable handle (with disposable needles). In these cases it is necessary to provide an easy mechanism to accomplish the rewind.
Spring Powered—Speed Control
The spring can be made with enough strength to give adequate torque to the needle for drilling through most bone applications. However, the rotational speed provided by the spring may be excessive and therefore, a means of controlling that speed is required.
Hand-Powered VidaPen I
It may be desirable to dispense with motors and springs altogether and power the rotation of the needle by hand. This would eliminate several potential problems associated with stored power devices and make the function totally dependent on the user.
A hinged grip that is squeezed by the user may be used to provide power to rotate the needle. Several mechanisms can be used to transfer the to-and-fro motion of the grip to rotational power to spin the needle. These are gear arrangements and/or lever/ratchet configurations.
A push handle may be used to propel a rod into the driver. This rod is fitted with spiral groves along the shank that mates with knobs in the gearbox to provide rotational power. This is mechanism is similar to Yankee screwdrivers. Two hands would be required—one to push the handle and the other to stabilize the driver.
An inertia motor may be used to drive the needle. This can be a flywheel or other spinning weight that will be used to rotate the needle. The user will provide rotation to the flywheel just prior to use by using any one of the mechanisms illustrated in
Ergonomic Configurations
A key to successful use of the VidaPen is to configure the design to allow a natural interface between the user and the device as it is applied to the patient. Consideration is made for a grip that allows the medic to control the device and hold it securely in a natural position. In addition, the device must “feel” like other common tools used by the medic and allow steady positioning during use. Coupled with this, the user must be able to see the target area and not have to assume an unnatural position to do so. Therefore, his/her eyes must be able to see the target area easily and in proper alignment throughout the procedure.
Mechanism to Allow Ergonomic Design
While ergonomics are important in the design of VidaPen, proper function is essential. In order to embody the mechanism in such a well-designed driver (handle) certain aspects of power transfer must be considered.
In some embodiments device 90 may be equipped with an on/off switch for starting and stopping the power supply. A battery recharger may be included in some models.
In some embodiments device 90 may include a plunger mechanism (not expressly shown) that is attached to the proximal end and designed to engage the interior surface of reservoir 91.
Broad Application:
VidaPen technology has great promise for almost any serious emergency that requires intravenous (IV) access to administer life-saving drugs or fluids, when traditional IV access is difficult or impossible. These life-threatening conditions include, but are not limited to:
NOTE: IO is to be used primarily as a “bridge” (temporary fluid and drug therapy) until conventional IV sites can be found and utilized. This occurs because IO fluids stabilize the patient and expand their vascular compartment.
Emergency Medicine Indications (VidaPen):
After acceptance in the emergency medical community as a reliable alternative for accessing the vascular system, VidaPen could become the standard of care for administering medications in life-threatening situations when IV access is difficult. Appropriately priced, the VidaPen could become required equipment for basic emergency kits:
Ambulances:
More than 35,000 Advanced Cardiac Life Support (ACLS) ambulances are in service in the U.S. Each is equipped with emergency drugs and devices. Most are required to carry intraosseous needles and paramedics are trained in their use for pediatric emergencies. Paramedics often experience great difficulty establishing IV access in life threatening emergencies such as drug overdoses, cardiac arrest and status epilepticus. Since they are the first on the scene in most serious emergencies, they would welcome a device like the VidaPen, which could help them rapidly, administer medications and treat the emergency before permanent damage to the patient occurs. There is nothing like VidaPen on the market and some patients desperately need this route for emergency drugs;
Emergency Rooms:
More than 4,000 emergency rooms in the U.S. are required to treat life-threatening emergencies like shock trauma and cardiac arrest. ERs are stocked with the latest devices and equipment to help patients receive state-of-the-art treatment. However, there is no more exasperating situation for the physician or potentially catastrophic condition for the critical patient, than the inability to establish intravenous access. VidaPen can provide a simple and straightforward solution for an extremely difficult clinical problem;
Hospital Crash Carts:
Hospitals are required to provide crash carts on every patient ward. It is estimated that 6,000 U.S. hospitals stock more than 60,000 crash carts. These crash carts are stocked with defibrillator, IV access devices, including central venous catheters, IV fluids and drugs for common emergencies. Nurses and other healthcare workers using these crash carts are often inexperienced in such emergencies and have difficulty establishing IV access. VidaPen can provide the long sought IV alternative in the difficult patient;
Military:
Automatic injectors are widely used in the military. During Desert Storm, combat soldiers carried an atropine auto-injector for nerve gas poisoning. Current auto-injectors are limited to intramuscular injections. The VidaPen could vastly expand the scope of treatment to include intravenous drugs, without having to be skilled in the technique of intravenous insertion.
Internal Medicine/Critical Care:
Most acute care hospitals in the U.S. operate Intensive Care Units (ICUs) for seriously ill patients. Establishing and maintaining venous access in these patients is often a challenge. VidaPen would be a welcome device for administration of drugs and fluids for these critical patients.
Cancer Applications (VidaVac):
In addition to the emergency medicine applications, where injection is the mode of operation, this technology can also be used to aspirate fluid. Thus, the VidaVac is ideally suited for the treatment and diagnosis of cancer.
Bone Marrow Harvest
For bone marrow transplants in cancer
Bone Marrow Diagnostics
For diagnosing cancer and hematological diseases
Infusion of Chemotherapy and Fluids
For cancer treatment, when IV access is difficult or veins have been destroyed by chemotherapy.
Secondary Applications:
VidaPen has great promise for many other diseases. Secondary applications will be developed after success of the primary applications. Some may evolve into primary markets. These include:
Neurosurgery (VidaVent);
Cranial vent (closed head injury requiring monitoring of intracranial pressure)
Stem Cell Harvest;
For regeneration of damaged tissue (heart muscle, articular surface, nerves and spinal cord, bone and spinal fusions)
Veterinary Market.
Intraosseous access has been used extensively in animal research. Increasing use of parenteral medications in companion animals accompanied by difficulty finding suitable veins to administer these drugs makes IO infusion an attractive alternative. The VidaVet appears ideally suited for these applications.
Epilepsy, An Example of VidaPen's Unique Solution:
Ten percent of the population experience a major seizure in their lifetime and more than 2,500,000 people in the United States have epilepsy. Grand mal seizures represent one of the most dramatic events in medicine. During the seizure, which usually lasts 60 to 90 seconds, patients typically fall to the ground, become rigid with trunk and extremities extended, and shake violently. The most dreaded progression of seizures is status epilepticus, a condition defined as a continuous seizure lasting more than 30 minutes or two or more seizures that occur without full conscious recovery between attacks. Convulsive status epilepticus requires urgent, immediate treatment. Patients are at risk for serious injury, hypoxemia, circulatory collapse, permanent brain damage and death. The overall mortality of convulsive status epilepticus is up to 35 percent.
Intravenous Access Required:
Intravenous access with a large bore needle/catheter must be established to administer anticonvulsant medications. These include a benzodiazepine followed by phenytoin and/or phenobarbital for immediate seizure control and prevention of further seizures. There are no satisfactory oral, rectal, or intramuscular medications that will control status epilepticus.
Clinical Need:
The problem facing clinicians and paramedics treating patients with status epilepticus is the difficulty establishing venous access. Without adequate venous lines none of the effective anticonvulsants can be given. During seizures the violent shaking makes accessing a satisfactory vein difficult. Often after the line is established, further shaking dislodges the IV or causes it to infiltrate.
Danger of Accidental Puncture:
Further, caregivers are at great risk of puncturing themselves with a needle when attempting to establish venous access in a patient during a seizure. Through no fault of their own, seizing patients, by jerking and thrashing around, turn the safest procedure into a terrifying venture. Doctors, nurses, and paramedics work in mortal fear of contracting AIDS and hepatitis through an inadvertent puncture with a contaminated needle.
Central Venous Access:
In an attempt to solve the venous access problem, emergency physicians and intensivists have turned to establishing a central line (intravenous catheter placed in a large central vein such as the subclavian or femoral vein). However, with this method, even under ideal conditions, there is an increased incidence of serious side effects such as pneumothorax, hemothorax, inadvertent puncture of a major artery, infection, venous thrombosis, and embolus. In the case of a patient with status epilepticus, this method becomes increasingly difficult and dangerous for all of the above-mentioned reasons. Therefore, most doctors are reluctant to even attempt a central line until seizures have ceased.
VidaPen provides alternative, safe IV access:
The VidaPen has been designed to quickly, and safely access the vascular system in difficult cases, like status epilepticus, giving medics the opportunity to administer crucial medications (see the Scientific Appendix for a more complete description of VidaPen's use in epilepsy).
Other Emergency Conditions that Will Benefit from the VidaPen:
Dialysis patients who often come to the emergency room in life threatening situations such as pulmonary edema (water on the lungs) or high potassium leading to cardiac arrest. These patients typically have troublesome or non-existent veins. The VidaPen could give these patients hope for a better quality of live and decrease their mortality.
Suicide attempts and drug overdoses often present in coma requiring immediate intravenous access to give antidotes and life saving medications such as Narcan. These patients usually have difficult venous access due to long term abuse of their veins. The VidaPen can give these patients an alternate access route while improving the safety of the healthcare workers.
Trauma victims often present in shock due to blood loss requiring swift replacement to save vital organs. Because of the shock condition (decreased blood pressure), veins collapse and are often impossible to find. The VidaPen can save precious minutes for paramedics and trauma surgeons responsible for their care.
Cardiac arrest, drug overdoses, diabetic ketoacidosis, arrhythmias, burns, stroke, coma, etc. VidaPen provides a logical, safe and easy alternative to IV access in all such serious emergencies.
Life-threatening medical emergencies affect millions annually. Standard treatment requires administering intravenous (IV) drugs and fluids. Yet, for more than 4 million patients annually this treatment is not available because intravenous lines cannot be readily established. For these patients, finding a suitable alternative treatment becomes a monumental and sometimes impossible task. Thousands of patients with such emergencies die because life saving medications cannot be administered.
An accepted alternative route to give IV medications is through the bone marrow (intraosseous, or IO, access). All drugs tested enter the circulation just as rapidly via the intraosseous route as they do when given intravenously. In fact, the bone marrow is considered a large non-collapsible vein. Currently, the IO route is used for alternative emergency access in pediatric patients, whose bones are soft enough to permit manual insertion of IO needles. However, no practical device is available for IO access in adults, because of their hard bones.
VidaPen I & II, New Capability for Emergency Medicine:
VidaPen is being developed to meet this clinical need. The VidaPen I is a small battery powered device that penetrates the bone with a hollow drill that provides IO access. VidaPen II is a small auto-injector that penetrates the bone with a hollow drill and automatically injects medications into the circulation in less than 3 seconds. VidaPen's approach vastly expands the usefulness of IO administration in the pediatric population and also, for the first time, makes possible the use of IO technology for the adult population.
VidaPen technology offers great promise for almost every serious emergency that requires rapid and reliable vascular access to administer life-saving drugs or fluids, when traditional IV access is difficult or impossible. Such emergencies include shock, trauma, cardiac arrest, drug overdoses, diabetic coma, burns, dehydration, seizures, allergic reactions, and arrhythmias. There are 100 million visits to emergency rooms annually. Statistics show that vascular access is difficult or impossible in 4 million patients annually.
Cancer, “Sometimes the Treatment is Worse than the Disease”:
Cancer patients often endure pain and discomfort in their quest for a cure. Among the most painful procedures these patients must encounter is bone marrow aspiration (biopsy). This arduous procedure is necessary to make the correct diagnosis, to monitor the success of treatment, or to undergo bone marrow harvesting prior to transplantation. More than 30,000 bone marrow transplants are performed in the US annually and over 200,000 bone marrow biopsies are performed. Bone marrow sampling is not a gentle procedure and is difficult for both the patient and the physician. The instrument used to penetrate the bone is a large nail-like device. Oncologists push with considerable force and twist on the handle to grind through the harder crest of the bone, into the softer marrow, Safety (contracting AIDS) is a major concern for oncologists, because repeated manipulation of a blood-contaminated needle is necessary.
VidaVac I & II, New Instruments in the Treatment of Cancer:
Instead of having to push and grind into the bone, VidaVac I is a small battery powered instrument that permits the oncologist to automatically drill into the marrow with minimal effort to withdraw specimens for diagnostics (biopsy). VidaVac II automatically withdraws marrow for transplantation. The end result is a safe, successful completion of bone marrow harvesting with less pain for the patient. It enables oncologists to treat patients in a kinder, gentler way, significantly decreasing risks for the doctor and time for the procedure. VidaVac is ideally suited for the treatment and diagnosis of cancer in the following situations:
Bone marrow harvest: For bone marrow transplants in cancer.
Bone marrow biopsy: For diagnosing cancer and hematological diseases.
Infusion of chemotherapy: For cancer treatment, when IV access is difficult.
Other Applications:
Stem cell harvest (VidaVac): Stem cells taken from the bone marrow are targeted for regeneration of damaged heart muscle, nerves, spinal cord, cartilage, and bone;
Neurosurgery (VidaProbe): Closed head injury requiring introduction of a probe for monitoring and controlling intracranial pressure;
Veterinary (VidaVet): Venous access is difficult but necessary in many companion animals.
Emergency venous access is essential for the treatment of many serious diseases and conditions. Yet, many patients experience extreme difficulty obtaining timely emergency treatment because of the inability to obtain or maintain venous access. VidaPen offers an alternative access route that can mean the difference between life and death. Currently there is nothing like VidaPen on the market and some patients desperately need this route for emergency drugs. Physicians and paramedics should readily adopt the VidaPen technology, because they universally embrace intraosseous (IO) access for emergencies in infants. The next logical step is to use the VidaPen for IO access in adults. Based on the clear need for an acceptable alternative method to deliver life saving medications when IV access is unavailable, the VidaPen should gain rapid acceptance, significantly penetrating this market. VidaVac affords oncologists a much-needed powered instrument for the diagnosis and treatment of cancer. Accessing the bone marrow is an essential, everyday procedure, which currently takes considerable effort. Oncologists should readily adopt this technology because of the simplicity and safety it offers their patients.
This application is a divisional of U.S. patent application Ser. No. 14/271,144 filed May 6, 2014, which is a divisional of U.S. patent application Ser. No. 12/331,979 filed Dec. 10, 2008, which is a Divisional of U.S. patent application Ser. No. 10/449,503, filed May 30, 2003, entitled “APPARATUS AND METHOD TO PROVIDE EMERGENCY ACCESS TO BONE MARROW,” which claims priority to U.S. Provisional Patent Application Ser. No. 60/384,756, filed May 31, 2002, entitled “APPARATUS AND METHOD TO ACCESS BONE MARROW.” The entire contents of each of the above-referenced disclosures are specifically incorporated herein by reference without disclaimer. This application is co-pending to patent application entitled, “Apparatus and Method to Access the Bone Marrow for Oncology and Stem Cell Applications”, Ser. No. 10/448,650, filed May 30, 2003; and co-pending to patent application entitled “Apparatus and Method to Access Bone Marrow”, Ser. No. 10/449,476, filed May 30, 2003, which claim priority from the same provisional application.
Number | Name | Date | Kind |
---|---|---|---|
1539637 | Bronner et al. | May 1925 | A |
2317648 | Siqveland et al. | Apr 1943 | A |
2419045 | Whittaker et al. | Apr 1947 | A |
2773501 | Young et al. | Dec 1956 | A |
3104448 | Morrow et al. | Sep 1963 | A |
3120845 | Horner et al. | Feb 1964 | A |
3173417 | Horner et al. | Mar 1965 | A |
3175554 | Stewart et al. | Mar 1965 | A |
3507276 | Burgess et al. | Apr 1970 | A |
3529580 | Stevens et al. | Sep 1970 | A |
3543966 | Ryan et al. | Dec 1970 | A |
3750667 | Pshenichny et al. | Aug 1973 | A |
3815605 | Schmidt et al. | Jun 1974 | A |
3835860 | Garretson | Sep 1974 | A |
3893445 | Hofsess | Jul 1975 | A |
3991765 | Cohen | Nov 1976 | A |
4021920 | Kirschner et al. | May 1977 | A |
4099518 | Baylis et al. | Jul 1978 | A |
4124026 | Berner et al. | Nov 1978 | A |
4142517 | Contreras Guerrero de Stavropoulos et al. | Mar 1979 | A |
4170993 | Alvarez | Oct 1979 | A |
4185619 | Reiss | Jan 1980 | A |
4194505 | Schmitz | Mar 1980 | A |
4258722 | Sessions et al. | Mar 1981 | A |
4262676 | Jamshidi | Apr 1981 | A |
4306570 | Matthews | Dec 1981 | A |
4333459 | Becker | Jun 1982 | A |
4381777 | Garnier | May 1983 | A |
4399723 | Marleau | Aug 1983 | A |
4441563 | Walton, II | Apr 1984 | A |
4469109 | Mehl | Sep 1984 | A |
4484577 | Sackner et al. | Nov 1984 | A |
4543966 | Islam et al. | Oct 1985 | A |
4553539 | Morris | Nov 1985 | A |
4578064 | Sarnoff et al. | Mar 1986 | A |
4605011 | Naslund | Aug 1986 | A |
4620539 | Andrews et al. | Nov 1986 | A |
4646731 | Brower | Mar 1987 | A |
4654492 | Koerner et al. | Mar 1987 | A |
4655226 | Lee | Apr 1987 | A |
4659329 | Annis | Apr 1987 | A |
4692073 | Martindell | Sep 1987 | A |
4711636 | Bierman | Dec 1987 | A |
4713061 | Tarello et al. | Dec 1987 | A |
4716901 | Jackson et al. | Jan 1988 | A |
4723945 | Theiling | Feb 1988 | A |
4758225 | Cox et al. | Jul 1988 | A |
4762118 | Lia et al. | Aug 1988 | A |
4772261 | Von Hoff et al. | Sep 1988 | A |
4787893 | Villette | Nov 1988 | A |
4793363 | Ausherman et al. | Dec 1988 | A |
4867158 | Sugg | Sep 1989 | A |
4919146 | Rhinehart et al. | Apr 1990 | A |
4921013 | Spalink et al. | May 1990 | A |
4935010 | Cox et al. | Jun 1990 | A |
4940459 | Noce | Jul 1990 | A |
4944677 | Alexandre | Jul 1990 | A |
4969870 | Kramer et al. | Nov 1990 | A |
4986279 | O'Neill | Jan 1991 | A |
5002546 | Romano | Mar 1991 | A |
5025797 | Baran | Jun 1991 | A |
5036860 | Leigh et al. | Aug 1991 | A |
5057085 | Kopans | Oct 1991 | A |
5074311 | Hasson | Dec 1991 | A |
5116324 | Brierley et al. | May 1992 | A |
5120312 | Wigness et al. | Jun 1992 | A |
5122114 | Miller et al. | Jun 1992 | A |
5133359 | Kedem | Jul 1992 | A |
5137518 | Mersch | Aug 1992 | A |
5139500 | Schwartz | Aug 1992 | A |
5145369 | Lustig et al. | Sep 1992 | A |
5172701 | Leigh | Dec 1992 | A |
5172702 | Leigh et al. | Dec 1992 | A |
5176643 | Kramer et al. | Jan 1993 | A |
5195985 | Hall | Mar 1993 | A |
5203056 | Funk et al. | Apr 1993 | A |
5207697 | Carusillo et al. | May 1993 | A |
5249583 | Mallaby | Oct 1993 | A |
5257632 | Turkel et al. | Nov 1993 | A |
5261877 | Fine et al. | Nov 1993 | A |
5269785 | Bonutti | Dec 1993 | A |
5271414 | Partika et al. | Dec 1993 | A |
5279306 | Mehl | Jan 1994 | A |
5312364 | Jacobs | May 1994 | A |
5312408 | Brown | May 1994 | A |
5315737 | Ouimet | May 1994 | A |
5324300 | Elias et al. | Jun 1994 | A |
5332398 | Miller et al. | Jul 1994 | A |
5333790 | Christopher | Aug 1994 | A |
5341823 | Manosalva et al. | Aug 1994 | A |
5348022 | Leigh et al. | Sep 1994 | A |
5357974 | Baldridge | Oct 1994 | A |
5368046 | Scarfone et al. | Nov 1994 | A |
5372583 | Roberts et al. | Dec 1994 | A |
5383859 | Sewell, Jr. | Jan 1995 | A |
5385553 | Hart et al. | Jan 1995 | A |
5389553 | Grubisich et al. | Feb 1995 | A |
5400798 | Baran | Mar 1995 | A |
5405348 | Anspach et al. | Apr 1995 | A |
5405362 | Kramer et al. | Apr 1995 | A |
5423824 | Akerfeldt et al. | Jun 1995 | A |
5431655 | Melker et al. | Jul 1995 | A |
5451210 | Kramer et al. | Sep 1995 | A |
5484442 | Melker et al. | Jan 1996 | A |
D369858 | Baker et al. | May 1996 | S |
5526821 | Jamshidi | Jun 1996 | A |
5529580 | Kusunoki et al. | Jun 1996 | A |
5549565 | Ryan et al. | Aug 1996 | A |
5554154 | Rosenberg | Sep 1996 | A |
5556399 | Huebner | Sep 1996 | A |
5558737 | Brown et al. | Sep 1996 | A |
5571133 | Yoon | Nov 1996 | A |
5586847 | Mattern, Jr. et al. | Dec 1996 | A |
5591188 | Waisman | Jan 1997 | A |
5595186 | Rubinstein et al. | Jan 1997 | A |
5601559 | Melker et al. | Feb 1997 | A |
5632747 | Scarborough et al. | May 1997 | A |
5672155 | Riley et al. | Sep 1997 | A |
5713368 | Leigh | Feb 1998 | A |
5724873 | Hillinger | Mar 1998 | A |
5733262 | Paul | Mar 1998 | A |
5752923 | Terwilliger | May 1998 | A |
5762639 | Gibbs | Jun 1998 | A |
5766221 | Benderev et al. | Jun 1998 | A |
5769086 | Ritchart et al. | Jun 1998 | A |
5779708 | Wu | Jul 1998 | A |
5800389 | Burney et al. | Sep 1998 | A |
5807277 | Swaim | Sep 1998 | A |
5810826 | Akerfeldt et al. | Sep 1998 | A |
5817052 | Johnson et al. | Oct 1998 | A |
5823970 | Terwilliger | Oct 1998 | A |
D403405 | Terwilliger | Dec 1998 | S |
5858005 | Kriesel | Jan 1999 | A |
5865711 | Chen | Feb 1999 | A |
5868711 | Kramer et al. | Feb 1999 | A |
5868750 | Schultz | Feb 1999 | A |
5873510 | Hirai et al. | Feb 1999 | A |
5885226 | Rubinstein et al. | Mar 1999 | A |
5891085 | Lilley et al. | Apr 1999 | A |
5911701 | Miller et al. | Jun 1999 | A |
5911708 | Teirstein | Jun 1999 | A |
5916229 | Evans | Jun 1999 | A |
5919172 | Golba, Jr. | Jul 1999 | A |
5924864 | Loge et al. | Jul 1999 | A |
5927976 | Wu | Jul 1999 | A |
5928238 | Scarborough et al. | Jul 1999 | A |
5941706 | Ura | Aug 1999 | A |
5941851 | Coffey et al. | Aug 1999 | A |
5960797 | Kramer et al. | Oct 1999 | A |
5980545 | Pacala et al. | Nov 1999 | A |
5993417 | Yerfino et al. | Nov 1999 | A |
5993454 | Longo | Nov 1999 | A |
6007496 | Brannon | Dec 1999 | A |
6017348 | Hart et al. | Jan 2000 | A |
6018094 | Fox | Jan 2000 | A |
6018230 | Casey | Jan 2000 | A |
6022324 | Skinner | Feb 2000 | A |
6027458 | Janssens | Feb 2000 | A |
6033369 | Goldenberg | Mar 2000 | A |
6033411 | Preissman | Mar 2000 | A |
6042585 | Norman | Mar 2000 | A |
6049725 | Emmert et al. | Apr 2000 | A |
6063037 | Mettermeier et al. | May 2000 | A |
6066938 | Hyodo et al. | May 2000 | A |
6071284 | Fox | Jun 2000 | A |
6080115 | Rubinstein | Jun 2000 | A |
6083176 | Terwilliger | Jul 2000 | A |
6086543 | Anderson et al. | Jul 2000 | A |
6086544 | Hibner et al. | Jul 2000 | A |
6096042 | Herbert | Aug 2000 | A |
6102915 | Bresler et al. | Aug 2000 | A |
6106484 | Terwilliger | Aug 2000 | A |
6110128 | Andelin et al. | Aug 2000 | A |
6110129 | Terwilliger | Aug 2000 | A |
6110174 | Nichter | Aug 2000 | A |
6120462 | Hibner et al. | Sep 2000 | A |
6135769 | Kwan | Oct 2000 | A |
6159163 | Strauss et al. | Dec 2000 | A |
6162203 | Haaga | Dec 2000 | A |
6183442 | Athanasiou | Feb 2001 | B1 |
6210376 | Grayson | Apr 2001 | B1 |
6217561 | Gibbs | Apr 2001 | B1 |
6221029 | Mathis et al. | Apr 2001 | B1 |
6228049 | Schroeder et al. | May 2001 | B1 |
6228088 | Miller et al. | May 2001 | B1 |
6238355 | Daum | May 2001 | B1 |
6247928 | Meller et al. | Jun 2001 | B1 |
6248110 | Reiley et al. | Jun 2001 | B1 |
6257351 | Ark et al. | Jul 2001 | B1 |
6267763 | Castro | Jul 2001 | B1 |
6273715 | Meller et al. | Aug 2001 | B1 |
6273862 | Privitera et al. | Aug 2001 | B1 |
6283925 | Terwilliger | Sep 2001 | B1 |
6283970 | Lubinus | Sep 2001 | B1 |
6287114 | Meller et al. | Sep 2001 | B1 |
6302852 | Fleming, III et al. | Oct 2001 | B1 |
6309358 | Okubo | Oct 2001 | B1 |
6312394 | Fleming, III | Nov 2001 | B1 |
6315737 | Skinner | Nov 2001 | B1 |
6325806 | Fox | Dec 2001 | B1 |
6328701 | Terwilliger | Dec 2001 | B1 |
6328744 | Harari et al. | Dec 2001 | B1 |
6358252 | Shapira | Mar 2002 | B1 |
6402701 | Kaplan et al. | Jun 2002 | B1 |
6419490 | Kitchings Weathers, Jr. | Jul 2002 | B1 |
6425888 | Embleton et al. | Jul 2002 | B1 |
6428487 | Burdorff et al. | Aug 2002 | B1 |
6443910 | Krueger et al. | Sep 2002 | B1 |
6458117 | Pollins, Sr. | Oct 2002 | B1 |
6468248 | Gibbs | Oct 2002 | B1 |
6478751 | Krueger et al. | Nov 2002 | B1 |
6488636 | Bryan et al. | Dec 2002 | B2 |
6523698 | Dennehey et al. | Feb 2003 | B1 |
6527736 | Attinger et al. | Mar 2003 | B1 |
6527778 | Athanasiou et al. | Mar 2003 | B2 |
6540694 | Van Bladel et al. | Apr 2003 | B1 |
6547511 | Adams | Apr 2003 | B1 |
6547561 | Meller et al. | Apr 2003 | B2 |
6550786 | Gifford et al. | Apr 2003 | B2 |
6554779 | Viola et al. | Apr 2003 | B2 |
6555212 | Boiocchi et al. | Apr 2003 | B2 |
6575919 | Reiley et al. | Jun 2003 | B1 |
6582399 | Smith et al. | Jun 2003 | B1 |
6585622 | Shum et al. | Jul 2003 | B1 |
6595911 | LoVuolo | Jul 2003 | B2 |
6595979 | Epstein et al. | Jul 2003 | B1 |
6613054 | Scribner et al. | Sep 2003 | B2 |
6616632 | Sharp et al. | Sep 2003 | B2 |
6620111 | Stephens et al. | Sep 2003 | B2 |
6626848 | Neuenfeldt | Sep 2003 | B2 |
6626887 | Wu | Sep 2003 | B1 |
6638235 | Miller et al. | Oct 2003 | B2 |
6656133 | Voegele et al. | Dec 2003 | B2 |
6689072 | Kaplan et al. | Feb 2004 | B2 |
6702760 | Krause et al. | Mar 2004 | B2 |
6702761 | Damadian et al. | Mar 2004 | B1 |
6706016 | Cory et al. | Mar 2004 | B2 |
6716192 | Orosz, Jr. | Apr 2004 | B1 |
6716215 | David et al. | Apr 2004 | B1 |
6716216 | Boucher et al. | Apr 2004 | B1 |
6730043 | Krueger et al. | May 2004 | B2 |
6730044 | Stephens et al. | May 2004 | B2 |
6749576 | Bauer | Jun 2004 | B2 |
6752768 | Burdorff et al. | Jun 2004 | B2 |
6752816 | Culp et al. | Jun 2004 | B2 |
6758824 | Miller et al. | Jul 2004 | B1 |
6761726 | Findlay et al. | Jul 2004 | B1 |
6796957 | Carpenter et al. | Sep 2004 | B2 |
6846314 | Shapira | Jan 2005 | B2 |
6849051 | Sramek et al. | Feb 2005 | B2 |
6855148 | Foley et al. | Feb 2005 | B2 |
6860860 | Viola | Mar 2005 | B2 |
6875183 | Cervi | Apr 2005 | B2 |
6875219 | Arramon et al. | Apr 2005 | B2 |
6884245 | Spranza, III | Apr 2005 | B2 |
6887209 | Kadziauskas et al. | May 2005 | B2 |
6890308 | Islam | May 2005 | B2 |
6905486 | Gibbs | Jun 2005 | B2 |
6930461 | Rutkowski | Aug 2005 | B2 |
6942669 | Kurc | Sep 2005 | B2 |
6969373 | Schwartz et al. | Nov 2005 | B2 |
7008381 | Janssens | Mar 2006 | B2 |
7008383 | Damadian et al. | Mar 2006 | B1 |
7008394 | Geise et al. | Mar 2006 | B2 |
7025732 | Thompson et al. | Apr 2006 | B2 |
7063672 | Schramm | Jun 2006 | B2 |
7137985 | Jahng | Nov 2006 | B2 |
7186257 | Kim | Mar 2007 | B2 |
7207949 | Miles et al. | Apr 2007 | B2 |
7226450 | Athanasiou et al. | Jun 2007 | B2 |
7229401 | Kindlein | Jun 2007 | B2 |
7670328 | Miller | Mar 2010 | B2 |
7699850 | Miller | Apr 2010 | B2 |
7811260 | Miller et al. | Oct 2010 | B2 |
7815642 | Miller | Oct 2010 | B2 |
7850620 | Miller et al. | Dec 2010 | B2 |
7951089 | Miller | May 2011 | B2 |
8038664 | Miller et al. | Oct 2011 | B2 |
8217561 | Fukuzawa et al. | Jul 2012 | B2 |
8419683 | Miller et al. | Apr 2013 | B2 |
8480632 | Miller et al. | Jul 2013 | B2 |
8506568 | Miller | Aug 2013 | B2 |
8668698 | Miller et al. | Mar 2014 | B2 |
8684978 | Miller et al. | Apr 2014 | B2 |
8690791 | Miller | Apr 2014 | B2 |
8715287 | Miller | May 2014 | B2 |
20010005778 | Ouchi | Jun 2001 | A1 |
20010014439 | Meller et al. | Aug 2001 | A1 |
20010047183 | Privitera et al. | Nov 2001 | A1 |
20010053888 | Athanasiou et al. | Dec 2001 | A1 |
20020042581 | Cervi | Apr 2002 | A1 |
20020055713 | Gibbs | May 2002 | A1 |
20020120212 | Ritchart et al. | Aug 2002 | A1 |
20020138021 | Pflueger | Sep 2002 | A1 |
20020151902 | Riedel et al. | Oct 2002 | A1 |
20030028146 | Aves | Feb 2003 | A1 |
20030032939 | Gibbs | Feb 2003 | A1 |
20030036747 | Le et al. | Feb 2003 | A1 |
20030050574 | Krueger | Mar 2003 | A1 |
20030114858 | Athanasiou et al. | Jun 2003 | A1 |
20030125639 | Fisher et al. | Jul 2003 | A1 |
20030153842 | Lamoureux et al. | Aug 2003 | A1 |
20030191414 | Reiley et al. | Oct 2003 | A1 |
20030195436 | Van Bladel et al. | Oct 2003 | A1 |
20030195524 | Barner | Oct 2003 | A1 |
20030199787 | Schwindt | Oct 2003 | A1 |
20030216667 | Viola | Nov 2003 | A1 |
20030225344 | Miller | Dec 2003 | A1 |
20030225364 | Kraft et al. | Dec 2003 | A1 |
20030225411 | Miller | Dec 2003 | A1 |
20040019297 | Angel | Jan 2004 | A1 |
20040019299 | Ritchart et al. | Jan 2004 | A1 |
20040034280 | Privitera et al. | Feb 2004 | A1 |
20040049128 | Miller et al. | Mar 2004 | A1 |
20040064136 | Papineau et al. | Apr 2004 | A1 |
20040073139 | Hirsch et al. | Apr 2004 | A1 |
20040092946 | Bagga et al. | May 2004 | A1 |
20040153003 | Cicenas et al. | Aug 2004 | A1 |
20040158172 | Hancock | Aug 2004 | A1 |
20040158173 | Voegele et al. | Aug 2004 | A1 |
20040162505 | Kaplan et al. | Aug 2004 | A1 |
20040191897 | Muschler | Sep 2004 | A1 |
20040210161 | Burdorff et al. | Oct 2004 | A1 |
20040215102 | Ikehara et al. | Oct 2004 | A1 |
20040220497 | Findlay et al. | Nov 2004 | A1 |
20050027210 | Miller | Feb 2005 | A1 |
20050040060 | Andersen et al. | Feb 2005 | A1 |
20050075581 | Schwindt | Apr 2005 | A1 |
20050085838 | Thompson et al. | Apr 2005 | A1 |
20050101880 | Cicenas et al. | May 2005 | A1 |
20050113716 | Mueller et al. | May 2005 | A1 |
20050119660 | Bourlion et al. | Jun 2005 | A1 |
20050124915 | Eggers et al. | Jun 2005 | A1 |
20050131345 | Miller | Jun 2005 | A1 |
20050148940 | Miller | Jul 2005 | A1 |
20050165328 | Heske et al. | Jul 2005 | A1 |
20050165403 | Miller | Jul 2005 | A1 |
20050165404 | Miller | Jul 2005 | A1 |
20050171504 | Miller | Aug 2005 | A1 |
20050182394 | Spero et al. | Aug 2005 | A1 |
20050200087 | Vasudeva et al. | Sep 2005 | A1 |
20050203439 | Heske et al. | Sep 2005 | A1 |
20050209530 | Pflueger | Sep 2005 | A1 |
20050215921 | Hibner et al. | Sep 2005 | A1 |
20050228309 | Fisher et al. | Oct 2005 | A1 |
20050261693 | Miller et al. | Nov 2005 | A1 |
20060011506 | Riley | Jan 2006 | A1 |
20060015066 | Turieo et al. | Jan 2006 | A1 |
20060036212 | Miller | Feb 2006 | A1 |
20060052790 | Miller | Mar 2006 | A1 |
20060074345 | Hibner | Apr 2006 | A1 |
20060079774 | Anderson | Apr 2006 | A1 |
20060089565 | Schramm | Apr 2006 | A1 |
20060115066 | Levien et al. | Jun 2006 | A1 |
20060122535 | Daum | Jun 2006 | A1 |
20060129082 | Rozga | Jun 2006 | A1 |
20060144548 | Beckman et al. | Jul 2006 | A1 |
20060149163 | Hibner et al. | Jul 2006 | A1 |
20060167377 | Ritchart et al. | Jul 2006 | A1 |
20060167378 | Miller | Jul 2006 | A1 |
20060167379 | Miller | Jul 2006 | A1 |
20060184063 | Miller | Aug 2006 | A1 |
20060189940 | Kirsch | Aug 2006 | A1 |
20060206132 | Conquergood et al. | Sep 2006 | A1 |
20070016100 | Miller | Jan 2007 | A1 |
20070049945 | Miller | Mar 2007 | A1 |
20070149920 | Michels et al. | Jun 2007 | A1 |
20070213735 | Saadat et al. | Sep 2007 | A1 |
20070270775 | Miller et al. | Nov 2007 | A1 |
20080015467 | Miller | Jan 2008 | A1 |
20080015468 | Miller | Jan 2008 | A1 |
20080045857 | Miller et al. | Feb 2008 | A1 |
20080045860 | Miller et al. | Feb 2008 | A1 |
20080045861 | Miller et al. | Feb 2008 | A1 |
20080045965 | Miller et al. | Feb 2008 | A1 |
20080140014 | Miller et al. | Jun 2008 | A1 |
20080215056 | Miller et al. | Sep 2008 | A1 |
20080221580 | Miller et al. | Sep 2008 | A1 |
20090069716 | Freeman et al. | Mar 2009 | A1 |
20090093677 | Smith | Apr 2009 | A1 |
20090194446 | Miller et al. | Aug 2009 | A1 |
20100204611 | Zambelli | Aug 2010 | A1 |
20110046507 | Herndon | Feb 2011 | A1 |
20110082387 | Miller et al. | Apr 2011 | A1 |
20110306841 | Lozman et al. | Dec 2011 | A1 |
20120165832 | Oostman, Jr. et al. | Jun 2012 | A1 |
Number | Date | Country |
---|---|---|
2138842 | Jun 1996 | CA |
2454600 | Feb 2003 | CA |
2320209 | May 1999 | CN |
2664675 | Dec 2004 | CN |
10057931 | Aug 2002 | DE |
0517000 | Dec 1992 | EP |
0807412 | Nov 1997 | EP |
1314452 | May 2003 | EP |
1421907 | May 2004 | EP |
1447050 | Aug 2004 | EP |
2457105 | Dec 1980 | FR |
2516386 | May 1983 | FR |
2130890 | Jun 1984 | GB |
H06-132663 | May 1994 | JP |
H10-52433 | Feb 1998 | JP |
2001-505076 | Apr 2001 | JP |
9208410 | May 1992 | WO |
9307819 | Apr 1993 | WO |
9631164 | Oct 1996 | WO |
9806337 | Feb 1998 | WO |
9852638 | Nov 1998 | WO |
9918866 | Apr 1999 | WO |
9952444 | Oct 1999 | WO |
0009024 | Feb 2000 | WO |
0056220 | Sep 2000 | WO |
0178590 | Oct 2001 | WO |
0241792 | May 2002 | WO |
02096497 | Dec 2002 | WO |
03015637 | Feb 2003 | WO |
2005072625 | Aug 2005 | WO |
2005110259 | Nov 2005 | WO |
2005112800 | Dec 2005 | WO |
2008033874 | Mar 2008 | WO |
2008081438 | Jul 2008 | WO |
2011123703 | Oct 2011 | WO |
Entry |
---|
“Proven reliability for quality bone marrow samples”, Special Procedures, Cardinal Health, 6 pages (2003). |
Astrom, K. Gunnar, “CT-guided Transsternal Core Biopsy of Anterior Mediastinal Masses,” Radiology 1996; 199:564-567 (May 1996). |
Astrom, K. Gunnar, “Automatic Biopsy instruments Used Through a Coaxial Bone Biopsy System with an Eccentric Drill Tip,” Acta Radiological, 1995; 36:237-242 (May 1995). |
Australian Exam Report on Patent Application No. 2003240970, 2 pages (Oct. 15, 2007). |
BioAccess.com, Single Use Small Bone Power Tool—How it Works, 1 page (Jun. 9, 2008). |
Buckley et al., CT-guided bone biopsy: Initial experience with commercially available hand held Black and Decker drill, European Journal of Radiology 61, pp. 176-180 (2007). |
Chinese Office Action; Application No. 200680021872.X; 8 pages (Nov. 6, 2009). |
Chinese Office Action; Application No. 200780000585.5; 15 pages (Nov. 9, 2010). |
Chinese Office Action; Application No. 200910006631.3; 12 pages (Mar. 11, 2010). |
Chinese Office Action, Application No. 2005800003261, 9 pages (Jan. 16, 2009). |
Chinese Office Action, Application No. 200780000590.6, 13 pages (Aug. 21, 2009). |
Communication Pursuant to Article 94(3) EPC, Application No. 05 712 091.7-1265, 4 pages (Apr. 8, 2008). |
Communication relating to the results of the partial International Search Report for PCT/US2005/002484, 6 pages (May 19, 2005). |
Cummins, Richard, et al, “ACLS-Principles and Practice”, ACLS-The Reference Textbook, American Heart Association, pp. 214-218 (2003). |
European Extended Search Report, Application No. EP08021732.6, 7 pages (Nov. 13, 2009). |
European Extended Search Report, Application No. EP10153350.3, 5 pages (Mar. 11, 2010). |
European Office Action and Search Report, Application No. 09150973.7, 8 pages (Oct. 23, 2009). |
European Office Action Communication, Application No. 08158699.2-1265/1967142, 10 pages (Nov. 4, 2008). |
European Office Action, Application No. EP03731475.4, 4 pages (Oct. 11, 2007). |
European Office Action; Application No. 09 155 111.9-2310; 3 pages (Nov. 25, 2009). |
European Search Report, Application No. 08158699.2-1265, 4 pages (Aug. 2008). |
F.A.S.T. 1 Intraosseous Infusion System with Depth-Control Mechanism Brochure, 6 pages (2000). |
Gunal et al., Compartment Syndrome After Intraosseous Infusion: An Experimental Study in Docs, Journal of Pediatric Survey, vol. 31, No. 11, pp. 1491-1493 (Nov. 1996). |
Hakan et al., CT-guided Bone Biopsy Performed by Means of Coaxial Biopsy System with an Eccentric Drill, Radiology, pp. 549-552 (Aug. 1993). |
International PCT Search Report and Written Opinion, PCT/US2005/002484, 15 pages (Jul. 22, 2005). |
International PCT Search Report and Written Opinion, PCT/US2004/037753, 16 pages (Jul. 8, 2005). |
International PCT Search Report, PCT/US03/17167, 8 pages (Sep. 16, 2003). |
International PCT Search Report, PCT/US03/17203, 8 pages (Sep. 16, 2003). |
International PCT Search Report, PCT/US2004/037753, 6 pages (Apr. 19, 2005). |
International Preliminary Report on Patentability, PCT/US2005/002484, 9 pages (Aug. 3, 2006). |
International Preliminary Report on Patentability, PCT/US2007/072202, 10 pages (Jan. 15, 2009). |
International Preliminary Report on Patentability, PCT/US2007/072217, 11 pages (Feb. 12, 2009). |
International Preliminary Report on Patentability, PCT/US/2007/072209, 10 pages (May 14, 2009). |
International Preliminary Report on Patentability, PCT/US/2007/078203, 13 pages (Mar. 26, 2009). |
International Preliminary Report on Patentability, PCT/US/2007/078204, 11 pages (Apr. 2, 2009). |
International Preliminary Report on Patentability, PCT/US/2007/078205, 10 pages (Mar. 26, 2009). |
International Preliminary Report on Patentability, PCT/US/2007/078207, 10 pages (Mar. 26, 2009). |
International Preliminary Report on Patentability, PCT/US08/52943, 7 pages (Oct. 15, 2009). |
International Preliminary Report on Patentability, PCT/US2007 /072217, 11 pages (Feb. 12, 2009). |
International Preliminary Report on Patentability, PCT/US2007/072209, 10 pages, (May 14, 2009). |
International Preliminary Report, PCT/US2005/002484, 9 pages (Aug. 3, 2006). |
International Search Report and Written Opinion for International Application No. PCT/US2006/025201, 18 pages (Jan. 29, 2007). |
International Search Report and Written Opinion, PCT/US08/500346, 12 pages (May 22, 2008). |
International Search Report and Written Opinion, PCT/US08/52943, 8 pages (Sep. 26, 2008). |
International Search Report and Written Opinion, PCT/US2007 /072202. 17 pages (Mar. 25, 2008). |
International Search Report and Written Opinion, PCT/US2007/078204, 14 pages (May 15, 2008). |
International Search Report and Written Opinion, PCT/US2007/078203, 15 pages (May 13, 2008). |
International Search Report and Written Opinion, PCT/US2007/078205, 13 pages (Sep. 11, 2007). |
International Search Report and Written Opinion, PCT/US2007/078207, 13 pages (Apr. 7, 2008). |
International Search Report and Written Opinion, PCT1US2007/078205, 13 pages (Sep. 11, 2007). |
International Search Report, PCT /US2007 /072217, 20 pages (Mar. 31, 2008). |
International Search Report, PCT/US2006/025201, 12 pages (Feb. 7. 2008). |
International Search Report, PCT/US2007/072209, 18 pages (Apr. 25, 2008). |
International Search Report, PCT/US2007/072217, 20 pages (Mar. 31, 2008). |
Japanese Office Action, Application No. 2004-508,669, (with English summary), 9 pages (Aug. 3, 2009). |
Japanese Office Action, Application No. 2004-508,670, (with English summary), 13 pages (Apr. 21, 2009). |
Vidacare Corporation Comments to Intraosseous Vascular Access Position Paper, Infusion NursesSociety, 6 pages (May 4, 2009). |
Liakat A. Parapia, Trepanning of trephines: a history of bone marrow biopsy, British Journal of Haematology, pp. 14-19 (2007). |
Michael Trotty, ““Technology (A Special Report)—The Wall Street Journal 2008 Technology Innovation Awards—This years winners include: an IV alternative, a better way to make solar panels, a cheap, fuel efficient car and a better way to see in the dark””, The Wall StreetJournal, Factiva, 5 pages (2008). |
Notification of the First Chinese Office Action, Application No. 200580003261.8, 3 pages (Mar. 21, 2008). |
Office Action for Canadian application 2,612,483, mailed Dec. 27, 2013. |
Office Action for Chinese application 201210169546.0, mailed Apr. 18, 2014. |
Office Action for Taiwanese application 093134480, dated Feb. 11, 2011. |
Office Action in Canadian Patent Application No. 2,612,483, mailed Aug. 22, 2014. |
Office Communication in European Application No. 08021732.6, dated Jul. 20, 2013. |
Official Action for European Application No. 03756317.8, 4 pages (Dec. 28, 2006). |
PCT Preliminary Report on Patentability, PCT/US/2008/050346, 8 pages (Jul. 23, 2009). |
“Pediatric Emergency, Intraosseous Infusion for Administration of Fluids and Drugs,www.cookgroup.com, 1 page (2000).” |
Pediatrics, Official Journal of the American Academy of Pediatrics, “2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care of Pediatric and Neonatal Patients: Pediatric Advanced Life Support”, Downloaded from www.pediatrics.org, Feb. 21, 2007. |
Richard Cummins et al, “ACLS-Principles and Practice”, ACLS-The Reference Textbook, American Heart Association, DD. pp. 214-218 (2003). |
Riley et al., “A Pathologist's Perspective on Bone Marrow Aspiration Biopsy: I. Performing a Bone Marrow Examination,”Journal of Clinical Laboratory Analysis 18, pp. 70-90 (2004). |
Number | Date | Country | |
---|---|---|---|
20150366569 A1 | Dec 2015 | US |
Number | Date | Country | |
---|---|---|---|
60384756 | May 2002 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14271144 | May 2014 | US |
Child | 14666391 | US | |
Parent | 12331979 | Dec 2008 | US |
Child | 14271144 | US | |
Parent | 10449503 | May 2003 | US |
Child | 12331979 | US |